About This Content

This section provides detailed clinical context and instructions for using the Zeposia (ozanimod) Dose Calculator. The information helps healthcare professionals understand the calculator’s inputs, interpret its outputs, and manage patient dosing schedules according to official prescribing guidelines. It is intended for educational purposes and is not a substitute for clinical judgment.

Outputs Explained

Upon entering the required patient data and confirming the safety checklist, the calculator generates a comprehensive, patient-specific dosing schedule. Key outputs include:

• Personalized Titration Schedule: A calendar-based, 7-day dose-titration plan showing the specific dates and required doses (0.23 mg for days 1-4, 0.46 mg for days 5-7).
• Maintenance Dose Calculation: The recommended maintenance dose (0.92 mg daily) starting from day 8. This dose is automatically adjusted to 0.46 mg daily if the patient is on a concomitant moderate CYP2C8 inhibitor.
• Clinical Alerts: Important warnings or contraindications based on user inputs, such as caution for moderate hepatic impairment or contraindication for severe hepatic impairment.

How to Use the Calculator

To generate an accurate dosing administration schedule, follow these steps:

1. Select Indication: Choose either Multiple Sclerosis (MS) or Ulcerative Colitis (UC).
2. Enter Start Date: Input the planned first day of treatment. The calendar will automatically populate based on this date.
3. Specify Hepatic Impairment: Select the patient’s status (None/Mild, Moderate, or Severe). Note that severe hepatic impairment (Child-Pugh C) is a contraindication.
4. Indicate Concomitant Medications: Check the box if the patient is taking a moderate CYP2C8 inhibitor (e.g., clopidogrel) to ensure the maintenance dose is adjusted.
5. Complete Safety Checklist: Confirm all pre-treatment assessments have been completed by checking each box. The “Calculate Schedule” button will remain disabled until all items are confirmed.

Dosing Overview

Zeposia requires a 7-day oral dose titration to reduce the risk of cardiac effects. The schedule is critical for safe initiation.

• Days 1–4: One 0.23 mg capsule once daily.
• Days 5–7: One 0.46 mg capsule once daily.
• Day 8 and thereafter: One 0.92 mg capsule once daily (maintenance dose).

Dose Adjustment: The maintenance dose is reduced to 0.46 mg once daily for patients with moderate hepatic impairment (Child-Pugh B) or those taking a moderate CYP2C8 inhibitor.

Switching to Zeposia

When switching a patient from another disease-modifying therapy to Zeposia, consider the half-life and mechanism of action of the prior drug to avoid additive immunosuppressive effects. A washout period may be necessary. For drugs with prolonged immune effects, such as alemtuzumab or natalizumab, initiation of Zeposia should be carefully considered. Always consult the full prescribing information for specific guidance on switching protocols.

Missed Dose Management

The management of a missed dose depends on the treatment phase:

• During the first 14 days (Titration Phase): If one or more doses are missed, the entire 7-day dose titration regimen must be reinitiated with a new starter pack. Use the calculator with the new start date to generate an updated schedule.
• After Day 14 (Maintenance Phase): If a dose is missed, the patient should take the next scheduled dose at their regular time. They should not take a double dose to make up for the missed one.

Safety Alerts

The calculator incorporates key contraindications from the Zeposia prescribing information. Treatment should not be initiated in patients with any of the following:

Frequently Asked Questions (FAQ)

1. Why is the maintenance dose reduced when taking a CYP2C8 inhibitor?

   Moderate CYP2C8 inhibitors (like clopidogrel) can significantly increase the concentration of ozanimod’s active metabolites in the body. Reducing the maintenance dose to 0.46 mg mitigates the risk of adverse effects from this drug-drug interaction.

2. What happens if I select “Severe” hepatic impairment in the calculator?

   The calculator will display a contraindication message and disable the calculation function. Zeposia is not recommended for patients with severe hepatic impairment (Child-Pugh C).

3. Is first-dose cardiac monitoring required for all patients?

   No. For most patients, routine first-dose cardiac monitoring is not required. However, an ECG is recommended prior to initiation to assess for pre-existing conduction abnormalities.

4. Why must I confirm all items on the pre-treatment safety checklist?

   The checklist ensures that critical safety assessments required by the prescribing information have been considered before treatment initiation. This helps prevent administration to patients with contraindications or high-risk conditions.

5. Can Zeposia be taken with or without food?

   Yes, Zeposia can be administered with or without food.

6. What are the available capsule strengths for Zeposia?

   Zeposia is available in three strengths: 0.23 mg, 0.46 mg, and 0.92 mg capsules, which are used for the dose titration and maintenance phases.

7. How do I re-start a patient who missed a dose on Day 6?

   Since the missed dose occurred within the first 14 days, the patient must stop treatment and reinitiate the full 7-day titration schedule starting from Day 1. You can use the calculator with a new start date to create the new schedule.

8. Can this calculator be used for pediatric patients?

   No. The safety and effectiveness of Zeposia in pediatric patients have not been established. This tool is intended for adult dosing only.

References

• ZEPOSIA (ozanimod) Full Prescribing Information. U.S. Food and Drug Administration.
• Zeposia (ozanimod) European Public Assessment Report (EPAR). European Medicines Agency.
• Zeposia Official Healthcare Professional Site. Bristol Myers Squibb.
• Cree BAC, Comi G, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, double-blind, double-dummy, active-controlled phase 3 trial. Lancet Neurol. 2019;18(11):1022-1033. PubMed.